Javle, M., Kelley, R. K., Roychowdhury, S., Weiss, K. H., Abou-Alfa, G. K., Macarulla, T., Sadeghi, S., Waldschmidt, D., Zhu, A. X., Goyal, L., Borad, M., Yong, W. P., Borbath, I., El-Khoueiry, A., Philip, P., Moran, S., Ye, Y., Ising, M., Lewis, N., & Bekaii-Saab, T. (n.d.). lBA28Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions. Annals of oncology, 29, . http://access.bl.uk/ark:/81055/vdc_100095324851.0x00003a